Kiprime Research Wins Largest-Ever Non-Clinical Primate Study Contract Since Its Establishment
On February 19, KiPrime Research, a subsidiary of BioToxtech and the No. 1 toxicology testing institution in Korea, announced that it has won the largest-ever non-clinical primate study contract since its establishment.
The contract is worth 2.45 million dollars (about 3.5 billion won), exceeding 25% of the previous year's sales. In 2022, KiPrime Research built a non-clinical primate testing facility in Osong, Chungcheongbuk-do that meets global standards. It obtained Good Laboratory Practice (GLP) certification for repeated-dose toxicity studies in non-clinical primates in 2023 and GLP certification for cardiovascular safety pharmacology studies in non-clinical primates in 2025.
In line with the growing demand for biopharmaceuticals, KiPrime Research is offering differentiated technologies such as liver and heart biopsy services, specialized administration for ophthalmic diseases, and immunoassay services. It has also established a dedicated TFT to internalize alternative testing method (NAMs) technologies, and is designing and building service roadmaps for each technology through collaboration with government ministries and participation in private consortia.
The BioToxtech Group provides end-to-end non-clinical services across the entire preclinical spectrum, including high-quality toxicity and efficacy studies using non-clinical primates, rodents, and non-rodents, bioanalytical services, and laboratory animal sales, all for new drug development. KiPrime Research is currently preparing for listing on the KOSDAQ market.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
CEO Kim Dongil said, "This contract is a case in which we directly penetrated the U.S. market, which can be regarded as the standard for global drug approvals, and it is highly meaningful in that KiPrime Research's competitiveness has been officially recognized," adding, "This year, we aim to achieve order intake of more than 30 billion won and to raise the proportion of overseas contracts to over 50%, and thereby leap forward as a truly global contract research organization (CRO)."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.